(Q35747990)

10 August 2017

1 reference

title

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

11

Geoffrey C Farrell

1 reference

10 August 2017

Shirley A Coverdale

1

1 reference

10 August 2017

Mahbub H Khan

2

1 reference

10 August 2017

Karen Byth

3

1 reference

10 August 2017

Rita Lin

4

1 reference

10 August 2017

Martin Weltman

5

1 reference

10 August 2017

Jacob George

6

1 reference

10 August 2017

Dev Samarasinghe

7

1 reference

10 August 2017

Christopher Liddle

8

1 reference

10 August 2017

James G Kench

9

1 reference

10 August 2017

Evelyn Crewe

10

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

The American Journal of Gastroenterology

10 August 2017

1 reference

10 August 2017

99

1 reference

10 August 2017

4

1 reference

10 August 2017

636-644

1 reference

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Natural history of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

JGH and Asia-Pacific consensus on prevention and management of gastrointestinal and liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Type C chronic hepatitis with the discovery of a small hepatocellular carcinoma 7 years after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or a clue to the flaws?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Interferon therapy prolonged life expectancy among chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Can the response to interferon treatment be predicted in patients with chronic active hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Histopathology of chronic hepatitis C in relation to epidemiological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

Development of hepatocellular carcinoma after longterm sustained complete response to interferon therapy: what is the mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.04085.X

10.1111/J.1572-0241.2004.04085.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference